Interactions of the Dimeric Triad of HIV-1 Aspartyl Protease with Inhibitors

Author： MAGER PETER   DE CLERCQ ERIK   FROEYEN MATHEUS   REINHARDT ROBERT  

Publisher： Taylor & Francis Ltd

ISSN： 1055-9612

Source： Drug Design and Discovery, Vol.18, Iss.2-3, 2003-04, pp. : 53-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synthesis of dibenzyl iminodiacetic derivatives as potential inhibitors of HIV-1 aspartyl protease

By Abalain C.   Langlois M.  

European Journal of Medicinal Chemistry, Vol. 33, Iss. 2, 1998-02 ,pp. : 155-160

Elsevier

Access to resources Recommend Favorite

Drug Interactions of HIV Protease Inhibitors

By Malaty L.I.  

Drug Safety, Vol. 20, Iss. 2, 1999-02 ,pp. : 147-169

Adis International

Access to resources Recommend Favorite

Structure-activity relationships of first bishydroxymethyl-substituted cage dimeric 4-aryl-1,4-dihydropyridines as HIV-1 protease inhibitors

By Hilgeroth A.   Lilie H.  

European Journal of Medicinal Chemistry, Vol. 38, Iss. 5, 2003-05 ,pp. : 495-499

Elsevier

Access to resources Recommend Favorite

Dimeric 4-Aryl-1,4-Dihydropyridines: Development of a Third Class of Nonpeptidic HIV-1 Protease Inhibitors

By  

Mini Reviews in Medicinal Chemistry, Vol. 2, Iss. 3, 2002-06 ,pp. : 235-245

Bentham Science Publishers

Access to resources Recommend Favorite

HIV-1 protease inhibitors in development

By Catamancio Simona La Seta   Rusconi Stefano  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 3, 2002-03 ,pp. : 387-395

Informa Healthcare

Access to resources Recommend Favorite